AMD3100/培利西林通过 CXCL12-KRT19 涂层克服胰腺和结直肠癌细胞的免疫抑制。
AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.
机构信息
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
Weill Cornell Medicine, New York, NY, USA.
出版信息
Br J Cancer. 2021 Jul;125(2):149-151. doi: 10.1038/s41416-021-01315-y. Epub 2021 Mar 26.
Abstract
A recent Phase 1 clinical study of the immunological effects of inhibiting the chemokine receptor, CXCR4, in patients with pancreatic ductal adenocarcinoma or colorectal cancer suggests that stimulation of CXCR4 on immune cells suppresses the intratumoural immune reaction. Here, we discuss how CXCR4 mediates this response, and how cancer cells elicit it.
摘要
最近一项关于抑制趋化因子受体 CXCR4 对胰腺导管腺癌或结直肠癌患者免疫影响的 1 期临床研究表明，免疫细胞上 CXCR4 的刺激抑制了肿瘤内的免疫反应。在这里，我们讨论 CXCR4 如何介导这种反应，以及癌细胞如何引发这种反应。
相似文献
1
AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.AMD3100/培利西林通过 CXCL12-KRT19 涂层克服胰腺和结直肠癌细胞的免疫抑制。
Br J Cancer. 2021 Jul;125(2):149-151. doi: 10.1038/s41416-021-01315-y. Epub 2021 Mar 26.
2
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response.CXCR4 抑制在人类胰腺和结直肠癌细胞中诱导整合免疫反应。
Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28960-28970. doi: 10.1073/pnas.2013644117. Epub 2020 Oct 30.
3
PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion.PIM1抑制通过抵消CXCR4上调和阻断CXCL12分泌，有效增强普乐沙福诱导的造血干细胞动员。
Leukemia. 2019 May;33(5):1296-1301. doi: 10.1038/s41375-019-0428-6. Epub 2019 Feb 28.
4
A role for the CXCR4-CXCL12 axis in the little skate, Leucoraja erinacea.CXCR4-CXCL12轴在小斑鳐（Leucoraja erinacea）中的作用。
Am J Physiol Regul Integr Comp Physiol. 2018 Aug 1;315(2):R218-R229. doi: 10.1152/ajpregu.00322.2017. Epub 2018 Apr 11.
5
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.CXCL12-CXCR4 信号轴赋予胰腺癌细胞对吉西他滨的耐药性：一种新的治疗靶点。
Br J Cancer. 2010 Nov 23;103(11):1671-9. doi: 10.1038/sj.bjc.6605968. Epub 2010 Nov 2.
6
CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.针对卵巢癌的 CXCL12/CXCR4 轴靶向双功能纳米药物递送系统。
Int J Nanomedicine. 2020 Aug 7;15:5701-5718. doi: 10.2147/IJN.S257527. eCollection 2020.
7
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.培利西林以剂量依赖的方式抑制趋化因子 SDF-1 和 CXCR4 介导的基质接触，从而增加 BCR-ABL+细胞对伊马替尼和尼罗替尼的敏感性。
Leuk Lymphoma. 2009 Oct;50(10):1676-86. doi: 10.1080/10428190903150847.
8
The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.按需添加培哚普利福（plerixafor）对粒细胞集落刺激因子动员的 CD34+造血细胞的 CXCR4 和黏附分子表达。
Transfusion. 2014 Sep;54(9):2325-35. doi: 10.1111/trf.12632. Epub 2014 Mar 28.
9
Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.最近在使用 CXCR4 拮抗剂 plerixafor（AMD3100， Mozobil™）方面的进展，以及其他 CXCR4 拮抗剂作为干细胞动员剂的潜力。
Pharmacol Ther. 2010 Dec;128(3):509-18. doi: 10.1016/j.pharmthera.2010.08.009. Epub 2010 Sep 15.
10
Production of human embryonic kidney 293T cells stably expressing C-X-C chemokine receptor type 4 (CXCR4) as a screening tool for anticancer lead compound targeting CXCR4.生产稳定表达 C-X-C 趋化因子受体 4（CXCR4）的人胚肾 293T 细胞作为针对 CXCR4 的抗癌先导化合物筛选工具。
Life Sci. 2022 Aug 15;303:120661. doi: 10.1016/j.lfs.2022.120661. Epub 2022 May 26.
引用本文的文献
1
Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress enhancing T cell responses and sensitizing cells to gemcitabine.开发一种CXCR4拮抗肽P12，以抑制胰腺癌进展、增强T细胞反应并使细胞对吉西他滨敏感。
RSC Med Chem. 2025 Jul 19. doi: 10.1039/d5md00488h.
2
Cancer-associated fibroblasts: dual roles from senescence sentinels to death regulators and new dimensions in therapy.癌症相关成纤维细胞：从衰老哨兵到死亡调节因子的双重作用及治疗新维度
Front Immunol. 2025 Jul 18;16:1635771. doi: 10.3389/fimmu.2025.1635771. eCollection 2025.
3
Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy.抑制CXCR4可降低乳腺癌免疫治疗中髓样细胞的免疫抑制作用。
Sci Rep. 2025 Feb 12;15(1):5204. doi: 10.1038/s41598-025-89882-5.
4
Targeting cytokine and chemokine signaling pathways for cancer therapy.针对细胞因子和趋化因子信号通路的癌症治疗。
Signal Transduct Target Ther. 2024 Jul 22;9(1):176. doi: 10.1038/s41392-024-01868-3.
5
Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma.针对胰腺导管腺癌高度促纤维增生和免疫抑制肿瘤微环境的靶向治疗
Cancers (Basel). 2024 Apr 11;16(8):1470. doi: 10.3390/cancers16081470.
6
Targeting neutrophils: Mechanism and advances in cancer therapy.靶向中性粒细胞：癌症治疗的机制与进展。
Clin Transl Med. 2024 Mar;14(3):e1599. doi: 10.1002/ctm2.1599.
7
Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials.定义肿瘤微环境中的癌症相关成纤维细胞（CAFs）：癌症免疫治疗的新机遇和临床试验的进展。
Mol Cancer. 2023 Oct 2;22(1):159. doi: 10.1186/s12943-023-01860-5.
8
Involvement of CXCL12/CXCR4 axis in colorectal cancer: a mini-review.CXCL12/CXCR4 轴在结直肠癌中的作用：小型综述。
Mol Biol Rep. 2023 Jul;50(7):6233-6239. doi: 10.1007/s11033-023-08479-1. Epub 2023 May 23.
9
Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment.克服肿瘤微环境中髓样细胞诱导的免疫抑制的策略。
Front Oncol. 2023 Apr 11;13:1116016. doi: 10.3389/fonc.2023.1116016. eCollection 2023.
10
Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis.肿瘤微环境丰富了干性特征：治疗抵抗和转移的结构事件。
Mol Cancer. 2022 Dec 22;21(1):225. doi: 10.1186/s12943-022-01682-x.
Zotero 插件